Abstract
Diabetes mellitus is a devastating disease and the World Health Organization (WHO) expects that the number of diabetic patients will increase to 300 million by the year 2025. A variety of peptides, known as protein transduction domains (PTDs) or cell-penetrating peptides (CPPs), have been recently characterized for their ability to translocate into live cells. Some studies have shown that this technology is useful for the treatment of diabetes. In islet isolation and transplantation, cell-permeable peptides deliver anti-apoptotic molecules such as inhibitors of the c-Jun NH2-terminal kinases (JNKs) to protect islets. In type 2 diabetes, a cell-permeable peptide of JNK inhibitor markedly improves insulin resistance and ameliorates glucose tolerance in diabetic mice. JNKs are classic stress-activated protein kinases and many cellular stresses have been shown to stimulate JNK activation. In this review, we show some of the most recent contributions to the advancement of knowledge of the JNK pathway and several possibilities for the treatment of diabetes using protein transduction technology and the JNK inhibitory peptide.
Keywords: Diabetes, c-Jun NH2-terminal kinase, JNK inhibitor, protein transduction technology, cell-permeable peptide, cell penetrating peptide, islet transplantation, apoptosis
Current Bioactive Compounds
Title: Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes
Volume: 6 Issue: 1
Author(s): Hirofumi Noguchi
Affiliation:
Keywords: Diabetes, c-Jun NH2-terminal kinase, JNK inhibitor, protein transduction technology, cell-permeable peptide, cell penetrating peptide, islet transplantation, apoptosis
Abstract: Diabetes mellitus is a devastating disease and the World Health Organization (WHO) expects that the number of diabetic patients will increase to 300 million by the year 2025. A variety of peptides, known as protein transduction domains (PTDs) or cell-penetrating peptides (CPPs), have been recently characterized for their ability to translocate into live cells. Some studies have shown that this technology is useful for the treatment of diabetes. In islet isolation and transplantation, cell-permeable peptides deliver anti-apoptotic molecules such as inhibitors of the c-Jun NH2-terminal kinases (JNKs) to protect islets. In type 2 diabetes, a cell-permeable peptide of JNK inhibitor markedly improves insulin resistance and ameliorates glucose tolerance in diabetic mice. JNKs are classic stress-activated protein kinases and many cellular stresses have been shown to stimulate JNK activation. In this review, we show some of the most recent contributions to the advancement of knowledge of the JNK pathway and several possibilities for the treatment of diabetes using protein transduction technology and the JNK inhibitory peptide.
Export Options
About this article
Cite this article as:
Noguchi Hirofumi, Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes, Current Bioactive Compounds 2010; 6 (1) . https://dx.doi.org/10.2174/157340710790711746
DOI https://dx.doi.org/10.2174/157340710790711746 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Current Pharmaceutical Design Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Role of the Sex Hormone Estrogen in the Prevention of Lipid Disorder
Current Medicinal Chemistry Advanced QSAR Methods Evaluated Polycyclic Aromatic Compounds Duality as Drugs and Inductors in Psychiatric Disorders
Current Organic Chemistry Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Novel Cinnamic Acid Derivatives as Potential PPARδ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies
Current Drug Discovery Technologies Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives
Current Drug Targets Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews ER Stress and Autophagy
Current Molecular Medicine Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV Resistant Glucagon-like Peptide-1 Analogues
Protein & Peptide Letters Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
Current Medicinal Chemistry